Jul 28, 2026
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
Read More
Jul 28, 2026
HAYA Therapeutics Receives FDA Fast Track Designation for HTX-001
Read More
Jul 16, 2026
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
Read More
Jun 23, 2026
CroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study
Read More
Jun 9, 2026
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors
Read More
Jun 7, 2026
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a firstin- class GIPR antagonist
Download PDF
1234